IMPL Profile
Impel Pharmaceuticals Inc., headquartered in Seattle, Washington, is a commercial-stage biopharmaceutical company that develops and markets treatments for central nervous system diseases in the United States. The company's main product is Trudhesa, a nasal spray formulation of dihydroergotamine designed for the acute treatment of migraines. This innovative approach aims to provide fast and effective relief for migraine sufferers.
In addition to Trudhesa, Impel is working on seweral other therapeutic candidates. These include INP105, a nasal formulation of olanzapine intended for the acute treatment of agitation and aggression in individuals with autism spectrum disorder, and INP107, a nasal formulation of carbidopa/levodopa for treating OFF episodes in Parkinson's disease, which has successfully completed a Phase IIa clinical trial. These developments reflect the company's commitment to addressing significant unmet needs in the field of central nervous system disorders.
Founded in 2008 and originally known as Impel NeuroPharma, Inc., the company rebranded to Impel Pharmaceuticals Inc. in April 2022. Through its innovative nasal drug delivery technology and focused product pipeline, Impel aims to improve the lives of patients with neurological conditions by providing more effective and accessible treatment options.
|
